OrbiMed’s Cytokinetics CYTK Stock Holding History

OrbiMed’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.2M	Buy	+25,800	New	+$1.85M	0.04%	119
2025 Q3	–	Sell	-1,077,000	Closed	-$35.6M	–	115
2025 Q2	$35.6M	Sell	1,077,000 -432,205	-29%	-$15M	0.89%	29
2025 Q1	$60.7M	Sell	1,509,205 -74,800	-5%	-$3.44M	1.45%	22
2024 Q4	$74.5M	Buy	1,584,005 +817,099	+107%	+$42.4M	1.53%	22
2024 Q3	$40.5M	Sell	766,906 -46,000	-6%	-$2.56M	0.74%	41
2024 Q2	$44M	Buy	812,906 +130,206	+19%	+$7.86M	0.87%	35
2024 Q1	$47.9M	Buy	+682,700	New	+$52.8M	0.88%	40

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OrbiMed's CYTK Position: Q2 2026 in Review

OrbiMed opened a new position in Cytokinetics (CYTK) in Q2 2026: 25,800 shares worth $2.2M. The stake represents 0.04% of the portfolio and ranks #119 among its holdings. This is a return to the name: OrbiMed previously reported a position in CYTK as recently as Q2 2025.

OrbiMed first reported a position in CYTK in Q1 2024 and has held it in 7 quarters since. The position peaked at $74.5M in Q4 2024. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

OrbiMed held 25,800 shares of Cytokinetics worth $2.2M as of Q2 2026.
Cytokinetics was a new OrbiMed position in Q2 2026.
Cytokinetics made up 0.04% of OrbiMed's portfolio in Q2 2026, its #119 holding.
OrbiMed first reported a position in Cytokinetics in Q1 2024 and has held it in 7 quarters since.
OrbiMed's Cytokinetics position peaked at $74.5M in Q4 2024.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.